Basis of Presentation and Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2026

Accounting Policies [Abstract]

Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the unaudited condensed consolidated statements of cash flows that sum to the total of the same such amounts shown in the unaudited condensed consolidated statements of cash flows (in thousands):


		Six Months Ended June 30, 2026								Six Months Ended June 30, 2025
		Beginning of period				End of period				Beginning of period				End of period
Cash and cash equivalents		$	177,695			$	384,985			$	319,589			$	253,637
Restricted cash			7,845				7,846				8,770				9,471
Total cash, cash equivalents and restricted cash shown in the unaudited condensed consolidated statements of cash flows		$	185,540			$	392,831			$	328,359			$	263,108

Schedule of Revenue Consist of Product Sales to Customers

The Company operates in one business segment. Results of its operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues consist of net product sales to customers, substantially all of which are sales in North America. Revenues by product are as follows (in thousands):


		Three Months Ended June 30,								Six Months Ended June 30,
		2026				2025				2026				2025
NUPLAZID		$	183,132			$	168,479			$	350,056			$	328,199
DAYBUE products			124,827				96,087				225,965				180,683
Product sales, net		$	307,959			$	264,566			$	576,021			$	508,882